Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 604 trials

Vulvar Squamous Cell Carcinoma: Pembrolizumab Study

We are studying whether Pembrolizumab can help shrink tumors in patients with vulvar squamous cell carcinoma before surgery. This trial also looks at how the treatment affects the immune system.

Vulvar Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinology

Severe Alcohol-Associated Hepatitis: INT-787 Study

We are testing a new medication, INT-787, for individuals with severe alcohol-associated hepatitis. The goal is to see if it can help slow down the progression of this serious liver disease.

Alcoholic Hepatitis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGynecology and ObstetricsNeurology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Prednisone for Idiosyncratic Hepatotoxicity

We are studying whether prednisone can help reduce liver damage in patients with idiosyncratic hepatotoxicity. The trial will also assess its safety and impact on quality of life compared to a placebo.

Liver Toxicity>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHepatologyInternal Medicine

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Major Depression: Samyr® Tablet Study

We are investigating whether Samyr® tablets can improve symptoms in patients with major depressive disorder who are not fully responding to their current treatment. The study compares Samyr® to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Psychosis in Alzheimer's: ITI-1284 Study

We are evaluating a new medication, ITI-1284, for treating psychosis in patients with Alzheimer's disease. The study aims to see if it is more effective than a placebo in improving symptoms.

Psychosis associated with Alzheimer’s Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Vaginal Progesterone for Fertility: Standard vs. New Formulation

We are comparing two formulations of vaginal progesterone to see which one better supports pregnancy in women undergoing fertility treatments. This study aims to improve pregnancy rates and assess safety for participants.

Infertility>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

HER2-Positive Gastric Cancer: Trastuzumab Deruxtecan Study

We are testing a new treatment combining Trastuzumab Deruxtecan with chemotherapy for patients with advanced HER2-positive gastric or GEJ cancer. The goal is to see if this combination works better than the current standard treatment.

Metastatic Gastric Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

RSV Vaccine Study for Immunocompromised Adults

We are studying how well the RSV vaccine works and its safety in immunocompromised patients aged 18 and older. This includes comparing the immune response after one and two doses of the vaccine.

Respiratory Syncytial Virus (RSV)1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementInfectious DiseasesInternal MedicinePulmonology

Axial Spondyloarthritis: NSAIDs vs. Biosimilar TNF Blockers

We are comparing the effectiveness of high-dose NSAIDs and a biosimilar TNF blocker for patients with axial spondyloarthritis who haven't responded to NSAIDs. The study will also look at side effects and inflammation levels.

Axial Spondyloarthritis3-6 monthsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Fungal Nail Infection: MOB015B Solution for Kids

We are studying a new topical solution for treating mild to moderate fungal infections of the nail in children aged 6 to 17. The goal is to see how well it works and how safe it is.

Distal Subungual Onychomycosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyInfectious DiseasesPediatrics